For common targeted therapies used in AR-NHL, IgG-based monoclonal antibodies (e.g., rituximab) and Alb are recycled through the neonatal Fc receptor (FcRn) pathway. This evidence concerns the gene ALB and non-Hodgkin lymphoma.